Lysophosphatidic acid receptor inhibition as a new multipronged treatment for rheumatoid arthritis

Annals of the Rheumatic Diseases

Volumn 73, Issue 1, 2014, Pages 298-305

  Orosa, Beatriz ^a   García, Samuel ^a   Martínez, Paula ^a   González, Antonio ^a   Gómez Reino, Juan J ^a,b   Conde, Carmen ^a  

^a Santiago University Clinical Hospital   (Spain)

^b UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRHEUMATIC AGENT; COLONY STIMULATING FACTOR 1; KI 16425; LYSOPHOSPHATIDIC ACID RECEPTOR; OSTEOCLAST DIFFERENTIATION FACTOR; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTHRITIS; ARTICLE; BONE EROSION; BONE METABOLISM; BONE MINERALIZATION; CARTILAGE INJURY; CELL DIFFERENTIATION; CONTROLLED STUDY; DISEASE SEVERITY; DRUG MECHANISM; HISTOPATHOLOGY; MOUSE; NONHUMAN; OSTEOBLAST; OSTEOCLASTOGENESIS; OSTEOLYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RECEPTOR BLOCKING; SYNOVITIS; WESTERN BLOTTING;

ARTHRITIS; AUTOIMMUNE DISEASES; RHEUMATOID ARTHRITIS;

ANIMALS; ARTHRITIS, EXPERIMENTAL; ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; CALCIFICATION, PHYSIOLOGIC; CELL DIFFERENTIATION; DISEASE MODELS, ANIMAL; ISOXAZOLES; MICE; MICE, INBRED C57BL; MICE, INBRED NOD; OSTEOBLASTS; OSTEOCLASTS; PROPIONATES; RECEPTORS, LYSOPHOSPHATIDIC ACID; SYNOVITIS;

EID: 84889644214     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2012-202832     Document Type: Article

References (45)

1. McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med 2011;365:2205-19.
2. Firestein GS. Evolving concepts of rheumatoid arthritis. Nature 2003;423:356-61. (Pubitemid 40852711)
3. Klareskog L, Catrina AI, Paget S. Rheumatoid Arthritis. Lancet 2009;373:659-72.
4. Bartok B, Firestein GS. Fibroblast-like synoviocytes. Key effector cells in rheumatoid arthritis. Immunol Rev 2010;233:233-55.
5. Scott DL. Radiological progression in established rheumatoid arthritis. J Rheumatol Suppl 2004;69:55-65. (Pubitemid 38327494)
6. Haynes DR, Crotti TN, Loric M, et al. Osteoprotegerin and receptor activator of nuclear factor kappa B ligand (RANKL) regulate osteoclast formation by cells in the human rheumatoid arthritic joint. Rheumatology 2001;40:623-30.
7. Walsh NC, Gravallese EM. Bone remodelling in rheumatic disease: a question of balance. Immunol Rev 2010;233:301-12.
8. Braun T, Schett G. Pathways for bone loss in inflammatory disease. Curr Osteoporos Rep 2012;10:101-8.
9. Walsh NC, Reinwald S, Manning CA, et al. Osteoblast function is compromised at sites of focal bone erosion in inflammatory arthritis. J Bone Miner Res 2009;24:1572-85.
10. Chen YF, Jobanputra P, Barton P, et al. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness. Health Technol Assess 2006;10:iii-iv, xi-xiii, 1-229.
11. Smolen JS, Weinblatt ME. When patients with rheumatoid arthritis fail tumour necrosis factor inhibitors: what is the next step? Ann Rheum Dis 2008;67:1497-8.
12. Lillegraven S, Prince FH, Shadick NA, et al. Remission and radiographic outcome in rheumatoid arthrtis: application of the 2011 ACR/EULAR remission criteria in an observational cohort. Ann Rheum Dis 2012;71:681-6.
13. Van den Broek M, Dirven L, Klarenbeek NB, et al. The association of treatment response and joint damage with ACPA-status in recent-onset RA: a subanalysis of the 8-year follow-up of the BeSt study. Ann Rheum Dis 2012;71:245-8.
14. Rezaei H, Saevarsdottir S, Forslind K, et al. In early rheumatoid arthritis, patients with a good initial response to methotrexate have excellent 2-year clinical outcomes, but radiological progression is not fully prevented: data from the methotrexate responders population in the SWEFOT trial. Ann Rheum Dis 2012;71:186-91.
15. Schett G. Cells of the synovium in rheumatoid arthritis. Osteoclasts. Arthritis Res Ther 2007;9:203.
16. Cejka D, Hayer S, Niederreiter B, et al. Mammalian target of rapamycin signaling is crucial for joint destruction in experimental arthritis and is activated in osteoclasts from patients with rheumatoid arthritis. Arthritis Rheum 2010;62:2294-302.
17. Sims NA, Green JR, Glatt M, et al. Targeting osteoclasts with zoledronic acid prevents bone destruction in collagen-induced arthritis. Arthritis Rheum 2004;50:2338-46. (Pubitemid 38924414)
18. Van Meeteren LA, Moolenaar WH. Regulation and biological activities of the autotoxin-LPA axis. P Lipid Res 2007;46:145-60. (Pubitemid 46654231)
19. Noguchi K, Ishii S, Shimizu T. Identification of p2y9/GPR23 as a novel G protein-coupled receptor for lysophosphatidic acid, structurally distant from de Edg family. J Biol Chem 2006;278:25600-6. (Pubitemid 36835313)
20. Lee CW, Rivera R, Gardell S, et al. GPR92 as a new G12713 and q-coupled lysophosphatidic acid receptor that increases cAMP, LPA5. J Biol Chem 2006;281:23589-97. (Pubitemid 44274133)
21. Umezu-Goto M, Tanyi J, Lahad J, et al. Lysophosphatidic acid production and action: validated targets in cancer? J Cell Biochem 2004;92:1115-40. (Pubitemid 44264223)
22. Santos AN, Riemann D, Santos AN, et al. Treatment of fibroblast-like synoviocytes with IFN-γ results in the down- regulation of autotaxin mRNA. Biochem Biophys Res Commun 1996;229:419-24. (Pubitemid 27029046)
23. Kehlen A, Lauterbach R, Santos AN, et al. IL-1 β- and IL-4-induced downregulation of autotaxin mRNA and PC-1 in fibroblast-like synoviocytes of patients with rheumatoid arthritis (RA). Clin Exp Immunol 2001;123:147-54. (Pubitemid 32118851)
24. Zhao C, Fernandes MJ, Prestwich GD, et al. Regulation of lysophosphatidic acid receptor expression and function in human synoviocytes: Implications for rheumatoid arthritis? Mol Pharmacol 2007;73:587-600.
25. Nochi H, Tomura H, Tobo M, et al. Stimulatory role of lysophosphatidic acid in cyclooxygenase-2 induction by synovial fluid of patients with rheumatoid arthritis in fibroblast-like synovial cells. J Immunol 2008;181:5111-19.
26. Orosa B, González A, Mera A, et al. Lysophosphatidic acid receptor 1 suppression sensitizes rheumatoid fibroblast-like synoviocytes to TNF-induced apoptosis. Arthritis Rheum 2012;64:2460-70.
27. Pradère J-P, Klein J, Grès S, et al. LPA1 receptor activation promotes renal interstitial fibrosis. J Am Soc Nephrol 2007;18:3110-18. (Pubitemid 350223970)
28. Ma L, Matsumoto M, Xie W, et al. Evidence for lysophosphatidic acid 1 receptor signaling in the early phase of neuropatic pain mechanisms in experiments using Ki16425, a lysophosphatidic acid 1 receptor antagonist. J Neurochem 2009;109:603-10.
29. Swaney JS, Chapman C, Correa LD, et al. A novel, orally active LPA1 receptor antagonist inhibits lung fibrosis in the mouse bleomycin model. J Pharmacol 2010;160:1699-713.
30. Castelino FV, Seiders J, Bain G, et al. Amelioration of dermal fibrosis by genetic deletion or pharmacologic antagonism of lysophosphatidic acid receptor 1 in a mouse model of scleroderma. Arthritis Rheum 2011;63:1405-15.
31. García S, Forteza J, López-Otin C, et al. Matrix metalloproteinase-8 deficiency increases joint inflammation and bone erosion in the K/BxN serum-transfer arthritis model. Arthritis Res Ther 2010;12:R224.
32. Kouskoff V, Korganow AS, Duchatelle V, et al. Organ-specific disease provoked by systemic autoimmunity. Cell 1996;87:811-22. (Pubitemid 26404281)
33. Jacobs JP, Ortiz-Lopez A, Campbell JJ, et al. Deficiency of CXCR2, but no other chemokine receptors, attenuates autoantibody-mediated arthritis in a murine model. Arthritis Rheum 2010;62:1921-32.
34. Chen M, Bilard E, Nigrovic PA, et al. Predominance of cyclooxygenase 1 over cyclooxygenase 2 in the generation of proinflammatory prostaglandins in autoantibody-driven K/BxN serum-transfer arthritis. Arthritis Rheum 2008;58:1354-65. (Pubitemid 351705925)
35. Lee SH, Rho J, Jeong D, et al. V-ATPase V0 subunit d2-deficient mice exhibit impaired osteoclast fusión and increased bone formation. Nat Med 2006;12:1403-9. (Pubitemid 44924499)
36. Hayashi M, Nakashima T, Taniguchi M, et al. Osteoprotection by semaphorin 3A. Nature 2012;485:64-74.
37. Lapierre DM, Tanabe N, Pereverzev A, et al. Lysophosphatidic Acid Signals through Multiple Receptors in Osteoclasts to Elevate Cytosolic Calcium Concentration, Evoke Retraction, and Promote Cell Survival. J Biol Chem 2010;285:25792-801.
38. David M, Wannecq E, Descotes F, et al. Cancer cell expression of autotaxin controls bone metastasis formation in mouse through lysophosphatidic acid-dependent activation of osteoclasts. PLoS One 2010;5:e9741.
39. Boucharaba A, Serve CM, Grès S, et al. Platelet-derived lysophosphatidic acid supports the progression of osteolytic bone metastases in breast cancer. J Clin Invest 2004;114:1714-25. (Pubitemid 40385527)
40. Boucharaba A, Serre CM, Guglielmi J, et al. The type 1 lysophosphatidic acid receptor is a target for thearpy in bone metastases. Proc Natl Acad Sci USA 2006;103:9643-8. (Pubitemid 43955878)
41. Gennero I, Laurencin-Dalicieux S, Conte-Auriol F, et al. Absence of the lysophosphatidic acid receptor LPA1 results in abnormal bone development and decreased bone mass. Bone 2011;49:395-403.
42. Contos JJA, Fukushima N, Weiner JA, et al. Requirement for the lpA1 lysophosphatidic acid receptor gene in normal suckling behaviour. Proc Natl Acad Sci USA 2000;97:13384-89.
43. Zheng Y, Kong Y, Goetzl EJ. Lysophosphatidic acid receptor-selective effects on Jurkat T cell migration through a Matrigel model basement membrane. J Immunol 2001;166:2317-22. (Pubitemid 32173464)
44. Stam JC, Micchiels F, van der Kammen RA, et al. Invasion of T-lymphoma cells: cooperation between Rho family GTPases and lysophospholipid receptor signaling. EMBO J 1998;17:4066-74 . (Pubitemid 28333990)
45. Kanda H, Newton R, Klein R, et al. Autotaxin, an ectoenzyme that produces lysophosphatidic acid, promotes the entry of lymphocytes into secondary lymphoid organs. Nature Immunol 2008;9:415-23. (Pubitemid 351405111)